CD34 and acute myeloid leukemia: Literature data also indicated that miR-181 inhibition could provide a new strategy for AML therapy [171], increasing the differentiation of myeloid progenitors, reducing the engraftment and the infiltration of leukemic HSPCs into BM and spleen, and ameliorating symptoms of leukemia in AML CD34+ HSPC xenograft mice [171].